(Q40980303)

25 September 2017

title

Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study (English)

1 reference

25 September 2017

1 reference

Alaa A Elzarkaa

1

1 reference

25 September 2017

Bassma El Sabaa

2

1 reference

25 September 2017

Doaa Abdelkhalik

3

1 reference

25 September 2017

Hassan Mansour

4

1 reference

25 September 2017

Mahmoud Melis

5

1 reference

25 September 2017

Waleed Shaalan

6

1 reference

25 September 2017

Mohamed Farouk

7

1 reference

25 September 2017

Eduard Malik

8

1 reference

25 September 2017

Amr A Soliman

9

1 reference

25 September 2017

publication date

13 January 2016

1 reference

Journal of Cancer Research and Clinical Oncology

25 September 2017

published in

1 reference

25 September 2017

volume

142

1 reference

25 September 2017

issue

5

1 reference

25 September 2017

page(s)

949-958

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-016-2116-5

25 September 2017

exact match

0 references

cites work

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Clinical trials in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Management strategies for recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Overexpression of Lewis(y) antigen protects ovarian cancer RMG-1 cells from carboplatin-induced apoptosis by the upregulation of Topo-I and Topo-II β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2116-5

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

21 January 2018

1 reference

12 December 2020

Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.

1 reference

12 December 2020

CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.

1 reference

12 December 2020

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

12 December 2020

Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications

1 reference

12 December 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

12 December 2020

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

12 December 2020

10.1007/S00432-016-2116-5

Identifiers

DOI

1 reference

release_mk25qeuraveufndq2adrmczb3i

25 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mk25qeuraveufndq2adrmczb3i

24 November 2022

mapped directly with Wikidata item

1 reference